Cancer vaccine has strong response in young girls (Reuters)


<p><a href="http://us.rd.yahoo.com/dailynews/rss/health/*http://news.yahoo.com/s/nm/20051217/hl_nm/glaxo_cervical_dc"><img src="http://us.news3.yimg.com/us.i2.yimg.com/p/nm/20051219/2005_12_19t081521_450x233_us_glaxo_cervical.jpg?x=130&y=67&sig=2tE7O0pXR_EPQWR_l7BwEg--" align="left" height="67" width="130" alt="An undated photo of GlaxoSmithKline's corporate headquarters in Brentford, UK. Girls aged 10 to 14 who received GlaxoSmithKline Plc's vaccine to prevent infection with the virus that causes cervical cancer had immune responses twice as strong as women 15-25 years old given the vaccine, the company said on Saturday, describing results of a late-stage trial. (Handout/Reuters)" border="0" /></a>Reuters - Girls aged 10 to 14 who received
GlaxoSmithKline Plc's vaccine to prevent infection with the
virus that causes cervical cancer had immune responses twice as
strong as women 15-25 years old given the vaccine, the company
said on Saturday, describing results of a late-stage trial.</p><br clear=all>